Molecular Templates and Takeda Oncology are teaming up to develop a new class of targeted biologic therapeutics for myeloma patients. The Food and Drug Administration (FDA) has now accepted the application for TAK-169, an Engineered Toxin Body (EBT) targeting CD38.

According to Eric Pooma, PhD, CEO and CSO of Molecular Templates, the new CD38 drug could help overcome resistance to existing CD38 targeted therapies.

SparkCures ID 352
Developed By Molecular Templates
Generic Name TAK-169
Treatment Classifications
  • Engineered Toxin Body (EBT)
Treatment Targets

Clinical Trials